Tagraxofusp not checked

Stemline Therapeutics, Inc. · SL-401

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 2 trial completes
Trials
3 active
7 in total · 2 in the EU
Targets
 

What this is

How it works
CD123 Interaction; Cytotoxin FDA class
How it’s given
“Tagraxofusp will be administered by intravenous infusion for 3 consecutive days during each 28-day cycle.”In the company’s words, NCT06456463 on ClinicalTrials.gov
Tested for
Acute Myeloid Leukemia
Main trialPhase 2
“This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.”In the company’s words, NCT06456463 on ClinicalTrials.gov
Other names
SL-401 · Elzonris · Tag

Other drugs for Acute Myeloid Leukemia

All 140 drugs for Acute Myeloid Leukemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials7

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting 9 Feb 2028 A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Phase 1/2Terminated Dec 2019 SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase 1/2Terminated Dec 2019 SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Phase 1/2Completed 1 Feb 2020 Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Phase 1/2Completed 27 Mar 2023 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Phase 2Authorised not given TAGVEN "Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic plasmacytoid dendritic cell neoplasm patients"
Phase 2Authorised not given Phase II study of standard of care therapy azacitidine (AZA) combined with venetoclax (VEN) and Tagraxofusp (TAG) in patients with higher-Risk chronic myelomonocytic Leukemia (CMML): the PATROL Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Tagraxofusp

Following is part of Solo: you see every change to Tagraxofusp the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in